Viamet Pharmaceuticals Newswire

Viamet Pharmaceuticals Newswire

Comprehensive Real-Time News Feed for Viamet Pharmaceuticals.

Results 1 - 11 of 11 in Viamet Pharmaceuticals

  1. Mycovia initiates two Phase 3 clinical trials to evaluate VT-1161 in patients with RVVCRead the original story w/Photo

    Sep 6, 2018 | Medical News

    Mycovia Pharmaceuticals, making its official debut as a company developing therapies in women's health and dermatology, today announced the initiation of two Phase 3 clinical trials called VIOLET to evaluate the safety and efficacy of its lead candidate, VT-1161, in patients with recurrent vulvovaginal candidiasis . Mycovia was created following the acquisition of Viamet Pharmaceuticals by NovaQuest Capital Management to develop VT-1161 for the treatment of fungal infections including RVVC and onychomycosis, a common infection of the nail.


  2. Vulvovaginal Candidiasis - Market Insights, Epidemiology and Market...Read the original story w/Photo

    Aug 9, 2018 | SBWire

    ... ies such as Candiplus (Profem), MAT2203 (Matinus Biopharma), NDV-3A (NovaDigm Therapeutics), VT-1161 (Viamet Pharmaceuticals) and other compelling treatments, are expected to impact the market size of Vulvovaginal Candidiasis


  3. Dermatomycoses Drug Market - Advanced technologies & growth...Read the original story

    Jun 11, 2018 |

    ... Co Ltd Dermala Inc Helix BioMedix Inc Novan Inc Sol-Gel Technologies Ltd TGV-Laboratories Viamet Pharmaceuticals Inc Vyome Biosciences Pvt Ltd On the basis of product, this report displays the production, revenue, price, market share and growth rate ...


  4. Onychomycosis Market Drivers 2018; Enthralling Growth at a CAGR of...Read the original story w/Photo

    Jun 4, 2018 | SBWire

    ... Inc. (Canada), Merz Pharma gmbh & co. kgaa (Germany), NanoBio Corporation (US), NovaBiotics Ltd (UK), Viamet Pharmaceuticals Inc. (US), Polichem SA (Switzerland) Onychomycosis Market - Segments Global onychomycosis market is segmented on the basis ...


  5. Tinea Pedis Treatment Market Is Expected to Be Reigned by North AmericaRead the original story

    May 9, 2018 | SBWire

    ... Competitive Landscape Some of the leading players in the global market for tinea pedis are GSK, Viamet Pharmaceuticals Exeltis USA, and Valeant. All of these market players are expected to concentrate on key product innovations over the course of ...


  6. Comprehensive Data and Key Insights on the Fungal Foot Infections...Read the original story w/Photo

    Apr 17, 2018 | SBWire

    ... companies mentioned in the study include Blueberry Therapeutics Ltd., Kaken Pharmaceutical Co. Ltd., Viamet Pharmaceuticals Inc., Biolab Farmaceutica Ltd., Helix BioMedix Inc., Novabiotics Ltd. and others. Browse Full Report with TOC- ...


  7. Vulvovaginal Candidiasis - Pipeline Insight, 2018 Market Report;...Read the original story w/Photo

    Mar 22, 2018 | SBWire

    ... NovaDigm Therapeutics, Pharmacon-Forschung Und Beratung GmbH, Scynexis Inc., Toltec Pharmaceuticals, Viamet Pharmaceuticals Inc., Zengen, & list continues. Please visit this link for more details: https://www. ...


  8. Worldwide Onychomycosis Market to Witness a Pronounce Growth Rate 7.9% of CAGR by 2023Read the original story w/Photo

    Jan 5, 2018 | SBWire

    ... Inc. (Canada), Merz Pharma gmbh & co. kgaa (Germany), NanoBio Corporation (US), NovaBiotics Ltd (UK), Viamet Pharmaceuticals Inc. (US), Polichem SA (Switzerland) Global Onychomycosis Market - Competitive Analysis: Characterized by the presence of ...


  9. Healthcare & Life Sciences Private Equity Deal Tracker: NovaQuest Acquires Viamet PharmaceuticalsRead the original story w/Photo

    Jan 4, 2018 | JD Supra

    Viamet , based in Durham, N.C., is a biopharmaceutical company focused on the discovery, development and commercialization of antifungal agents based on its proprietary metalloenzyme medicinal chemistry platform. NovaQuest Capital Management , based in Raleigh, N.C., is private equity and venture capital firm focused on investing in life sciences and healthcare through its NovaQuest Biopharma and NovaQuest Private Equity platforms.


  10. NovaQuest Capital Management to Acquire Viamet Pharmaceuticals and the VT-1161 Antifungal ProgramRead the original story

    Jan 2, 2018 | Venture Capital Access Online

    Viamet Pharmaceuticals , Inc. today announced that it has entered into an agreement with NovaQuest Capital Management, L.L.C. for the acquisition of Viamet Pharmaceuticals, including the company's product candidate, VT-1161, which successfully completed Phase 2b clinical trials for the treatment of recurrent vulvovaginal candidiasis and onychomycosis, or fungal nail infection. Upon closing of the acquisition, Viamet Pharmaceuticals will be a portfolio company of NovaQuest Capital, which will focus on further development of VT-1161 and related assets.


  11. NovaQuest Capital to buy Viamet PharmaceuticalsRead the original story

    Jan 3, 2018 | PE Hub

    NovaQuest Capital Management has agreed to acquire drug developer Viamet Pharmaceuticals . No financial terms were disclosed.